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Hydroxyethyl starch or saline for 
fluid resuscitation in intensive care
Myburgh et al., N Engl J Med 2012; 367: 1901–1911; doi:10.1056/
NEJMoa1209759
Despite decades of study, the optimal type of intravenous fluid 
for resuscitation of critically ill patients remains controversial. 
Colloidal solutions have the theoretical advantage of maximiz-
ing intravascular volume expansion while minimizing fluid 
administration. Despite the results of recent large clinical trials 
suggesting that infusion of colloidal intravenous hydroxyethyl 
starch (HES) increases the risk of adverse events, including acute 
kidney injury, some still advocate the use of intravenous colloid, 
including HES, in particular clinical scenarios. In the Crystalloid 
Versus Hydroxyethyl Starch Trial (CHEST), 7000 patients in 32 
adult medical/surgical intensive care units (ICUs) in Australia 
and New Zealand were randomized to receive either 6% HES 
(130/0.4) in 0.9% saline or 0.9% saline for all fluid resuscitation 
in the ICU until discharge, death, or 90 days after randomiza-
tion. Patients were eligible if the treating clinician judged them 
to require fluid resuscitation defined as intravenous bolus of fluid 
above that required for maintenance or replacement fluids at any 
time during the patient’s ICU admission. The volume and rate 
of fluid were determined by the treating clinicians, who were 
blinded to treatment groups. There was no difference in the pri-
mary outcome of 90-day mortality between treatment groups 
(Figure), and there was no evidence of benefit from HES in any of 
the six prospectively designated subgroups. Patients in the HES 
study arm did, however, have a significantly increased risk of 
need for renal replacement therapy (relative risk 1.21).
Particular strengths of this study include its large size, 
randomized double-blind design, and use of prespecified sub-
groups to assess whether key clinical characteristics influenced 
response to treatment. Weaknesses include the low incidence 
of mortality in both groups, which may have occurred at least 
in part due to inclusion of patients undergoing elective sur-
gery, and the lack of a standardized protocol for goal-directed 
therapy that some proponents of colloid therapy consider to 
be important for patient management. However, given the lack 
of benefit in any subgroup and an increase in adverse events, 
including the need for renal replacement therapy, the CHEST 
study provides compelling data arguing against the routine use 
of HES for patients in the intensive care setting.
Michael Ross
Soluble FLT1 controls podocyte 
morphology and glomerular 
barrier function
Jin et al., Cell 2012; 151: 384–399; doi:10.1016/j.cell.2012.08.037
It is well known that, in the kidney, vascular endothelial growth 
factor (VEGF) is required for maintenance of the glomeru-
lar microvasculature and kidney function. VEGF acts mainly 
through two receptor tyrosine kinases, VEGFR-1 (fms-like 
tyrosine kinase-1, FLT1) and VEGFR-2, which are expressed by 
endothelial cells. VEGF also binds to neuropilin-1 and neuropi-
lin-2, both of which may function to enhance VEGFR-2 signaling. 
In the glomerulus, podocytes produce VEGF in vast amounts. 
Podocyte-specific deletion or overexpression of VEGF during 
development leads to dramatic and distinct glomerular pheno-
types, with major defects within the glomerular endothelial cell 
compartment. Furthermore, VEGF production by the podocyte is 
also necessary to maintain the integrity of the mature glomerular 
filtration barrier. Although the role of VEGF production by podo-
cytes is well established, the expression and function of VEGF 
receptors in the glomerulus still are incompletely understood. In 
addition, the FLT1 gene, besides encoding the full-length vari-
ant, encodes a soluble truncated form (sFLT1) that retains the 
ligand-binding domain but lacks the transmembrane and tyrosine 
kinase domains. The function of this soluble form remains mostly 
unknown, and it is hypothesized that it works as a decoy VEGF 
receptor. Jin et al. found that, unexpectedly, sFLT1 is produced 
by podocytes and by other pericytes. Podocyte-specific deletion 
of sFLT1 leads to proteinuria and cytoskeletal rearrangements, 
because sFLT1 seems to be involved in podocyte adhesion and 
the formation of podocyte foot processes. Other changes can be 
observed in extrarenal tissues when sFLT1 is globally deleted, with 
increased vascularity and a lower number of pericytes that dis-
play aberrant morphology. The authors also show that sFLT1 has 
an autocrine action on podocytes that occurs by binding of the 
molecule to the lipid raft GM3 ganglioside. Upon binding, sFLT1 
mediates clustering of syndecans and nephrin, and increases both 
syndecan and nephrin phosphorylation, with profound effects on 
actin polymerization (Figure).
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Kaplan–Meier estimates of the probability of survival of patients 
receiving either 6% HES (130/0.4) or saline. The P value was calculated 
by means of the log-rank test.
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Interestingly, these events are completely independent of the 
presence or absence of VEGF, confirming the complexity of this 
system and the need of further investigation in this area, which 
appears more and more relevant to glomerular health.
Maria Pia Rastaldi
PTH-independent regulation of 
blood calcium concentration by the 
calcium-sensing receptor
Loupy et al., J Clin Invest 2012; 122: 3355–3367; doi:10.1172/JCI57407
Extracellular fluid calcium levels are tightly controlled as a 
result of a delicate interplay between the parathyroid gland, 
bone, kidney, and gut. The Ca2+-sensing receptor (CaSR) 
expressed on parathyroid cells regulates parathyroid hor-
mone (PTH) secretion. CaSR is also expressed in other organs, 
such as the kidney, but the biological significance is poorly 
understood. In this study, Loupy et al. investigated the role 
of extraparathyroid CaSR using a rat model with thyropar-
athyroidectomy (removing PTH and calcitonin), which was 
PTH-supplemented. Chronic inhibition of CaSR selectively 
increased renal tubular calcium absorption and blood calcium 
concentration independently of PTH secretion and without 
altering intestinal calcium absorption. CaSR inhibition also 
increased blood calcium concentration after bisphosphonate 
pretreatment, showing that blood calcium did not increase 
from a bone source. In in vitro microperfusion experiments, 
CaSR inhibitors increased calcium reabsorption and paracel-
lular pathway permeability in the thick ascending limb of the 
loop of Henle (TAL) but did not change NaCl reabsorption. 
Thus, extraparathyroid CaSR participates in the regulation of 
extracellular fluid calcium independently of PTH.
This model mainly involves the TAL, in which an increase 
in calcium reabsorption occurs through a specific increase in 
the paracellular pathway permeability to calcium and is inhib-
ited by calcimimetics, opening up the possibility that these 
drugs may be helpful in treating the hypocalcemia of primary 
hypoparathyroidism.
Jai Radhakrishnan
Association of low serum 
25-hydroxyvitamin D levels and 
acute kidney injury in the critically ill
Braun et al., Crit Care Med 2012; 40: 3170–3179; doi:10.1097/
CCM.0b013e318260c928
There has been increased interest in the role of vitamin D in 
regulating inflammation, as vitamin D receptors are present on 
the surface of T cells and activated B cells, and vitamin D sup-
presses binding of nuclear factor-kB to nuclear DNA. Braun and 
colleagues report an association between pre-hospital-admission 
25-hydroxyvitamin D3 concentration in 2075 patients and the 
risk of developing acute kidney injury (AKI) in the hospital.
The relative risk of AKI was 1.72 for those who were vitamin 
deficient with 25-hydroxyvitamin D3 concentrations ≤15 ng/
ml and 1.27 for those with vitamin D insufficiency 15–30 ng/
ml as compared with 1.0 for those with normal values greater 
than 30 ng/ml. However, although not significantly different, 
patients in the lowest 25-hydroxyvitamin D3 tertile also tended 
to have higher baseline mean serum creatinine values, 1.57 mg/
dl compared with 1.49 mg/dl for those with 15–30 ng/ml and 
compared with 1.34 mg/dl for those with values greater than 30 
ng/ml. Even though the peak serum creatinine was statistically 
greater for those who were 25-hydroxyvitamin D3 deficient, there 
were no differences in the proportion of patients who required 
renal replacement therapy. On follow-up, survival was greater in 
the patients in the highest 25-hydroxyvitamin D3 tertile.
This report adds to previous studies that have observed an 
association between 25-hydroxyvitamin D3 concentrations and 
outcome in critically ill patients. But other reports have shown 
that patients with background chronic diseases, including diabetes, 
rheumatoid arthritis, ischemic heart disease, and heart failure, tend 
to have lower 25-hydroxyvitamin D3 concentrations. However, 
it is unclear whether reduced 25-hydroxyvitamin D3 concentra-
tions are a primary risk factor for developing AKI or whether they 
merely reflect an association with preexistent comorbidity and 
chronic disease, which then increases susceptibility to AKI. Thus, 
a prospective interventional randomized clinical trial is required 
to determine whether 25-hydroxyvitamin D3 has a major role in 
reducing the risk of AKI and mortality in critically ill patients.
Andrew Davenport
A working model showing that sFLT1 patching induces 
phosphorylation of the conserved EFYA motif of syndecan. This 
C-terminal EFYA motif mediates signaling through recruitment of PDZ 
domain−containing proteins. HS, heparan sulfate.
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